Invion has announced that Hong Kong based The Cho Group will acquire 15.03% of Invion for a total of A$656,682 through a private placement. A restructuring of Invion's board will include the addition of two members of The Cho Group. According to Invion, "The company intends to use the proceeds of the investment for working capital as it continues to market the … [Read more...] about Invion announces deal with the Cho Group
News
Arch Biopartners to begin Phase 1 trial of AB569
Arch Biopartners said that it has begun manufacturing clinical trial supplies for a Phase 1 study of its AB569 sodium nitrite/ethylenediaminetetraacetic acid (EDTA) inhalation solution for the treatment of antibiotic-resistant bacterial lung infections, and the trial will begin as soon as the supplies are available. The study will evaluate PK and safety data of … [Read more...] about Arch Biopartners to begin Phase 1 trial of AB569
United Therapeutics to collaborate with Respira on development of RT234 DPI for the treatment of pulmonary hypertension
Respira Therapeutics has announced that United Therapeutics will fund the development of Respira's RT234 DPI for the treatment of pulmonary hypertension. United Therapeutics will get an exclusive license for the product in North America and will be the lead investor in Respira's Series B financing round. Respira will continue to develop RT234 for other … [Read more...] about United Therapeutics to collaborate with Respira on development of RT234 DPI for the treatment of pulmonary hypertension
MVP announces distribution deals for spacers in US and for Penthrox inhaler in Russia
Medical Developments International (MVP) has announced distribution deals for its compact anti-static space chambers in the US and for its Penthrox methoxyflurane inhaler in Russia. All Walmart and Kmart pharmacies in the US will carry MVP spacers. In Russia, JSC Lancet will be the distributor for Penthrox in a deal that includes milestone payments of AUD $2.3 … [Read more...] about MVP announces distribution deals for spacers in US and for Penthrox inhaler in Russia
Amneal Pharmaceuticals launches generic mometasone furoate nasal spray
Amneal Pharmaceuticals initiated shipments of its generic version of Nasonex mometasone furoate nasal spray on April 4, 2017, the company said. According to Amneal, the mometasone furoate nasal spray is its "first pharmaceutical product in spray form"; the company also markets a generic tobramycin inhalation solution. Amneal Executive VP of Sales and … [Read more...] about Amneal Pharmaceuticals launches generic mometasone furoate nasal spray
Inhalation Asia extends early bird registration deadline
The Inhalation Asia conference, which will take place in Hong Kong September 13-15 has extended its early bird registration period due to "an issue with the beta version of the website registration module." The new early bird deadline is May 5, with full registration costing HKD 3,800 up until that date and HKD 5,000 after that date. Student registration is HKD … [Read more...] about Inhalation Asia extends early bird registration deadline
Vectura to get milestone payment after launch of Breelib nebulizer in Poland
Vectura has announced that it will receive a €5 million milestone now that Bayer AG has launched the Breelib nebulizer for Ventavis iloprost inhalation solution in Poland. Breelib is an adaptation of Vectura’s FOX handheld smart nebulizer, which Vectura acquired along with its developer, Activaero, in 2014. In addition to the initial milestone, Vectura is eligible … [Read more...] about Vectura to get milestone payment after launch of Breelib nebulizer in Poland
Evoke Pharma reports agreement with FDA regarding PK trial design for Gimoti
According to Evoke Pharma, the company has reached an agreement with the FDA on design of a PK trial for its Gimoti metoclopramide nasal spray for the treatment of diabetic gastroparesis. The company said that results of the PK trial are expected later this year, with an NDA submission expected no later than early 2018. The company has previously announced that the … [Read more...] about Evoke Pharma reports agreement with FDA regarding PK trial design for Gimoti
GSK recalls almost 600,000 Ventolin inhalers in US
GSK has voluntarily recalled 593,088 Ventolin inhalers manufactured at its Zebulon, North Carolina facility due to an "Elevated number of units with out of specification results for leak rate." The lots involved in the level 2 recall, which was initiated on March 22, 2017, were distributed throughout the United States and Puerto Rico. In 2015, GSK recalled … [Read more...] about GSK recalls almost 600,000 Ventolin inhalers in US
Nemera to develop inhaled nanoparticle delivery devices as part of Project Cupido
Device company Nemera has announced that it will develop devices for the delivery of inhaled nanoparticles for the treatment of cardiovascular disease as part of the Cupido (Cardio Ultraefficient Nanoparticles For Inhalation Of Drug Products) consortium. The Cupido project, funded by the €6 million from the EU Horizon 2020 Framework Program, has set as its goal, … [Read more...] about Nemera to develop inhaled nanoparticle delivery devices as part of Project Cupido